Stockreport

Actuate Receives FDA Orphan Drug Designation for Elraglusib for Treatment of Soft Tissue Sarcomas

Actuate Therapeutics, Inc. - Common stock  (ACTU) 
PDF Elraglusib is a Class-Leading GSK-3ß Inhibitor with a Novel, Multimodal Mechanism of Action in Multiple Refractory Cancer TrialsOrphan Drug Designation in Soft Tissue Sa [Read more]